Amgen Announces Initiation of Phase 3 Trial to Evaluate the Impact of Treating Anemia with Darbepoetin Alfa

06-Sep-2005

Amgen announced that it will initiate a Phase 3 randomized, placebo-controlled, double-blind, multicenter, multi-national trial to evaluate the effect of anemia treatment with darbepoetin alfa on morbidity and mortality in patients with heart failure.

"Amgen's decision to proceed with its Phase 3 trial in heart failure is driven both by results from epidemiological studies, as well as by our recently completed Phase 2 pilot studies of anemia treatment in heart failure patients which provided us with encouraging results," said Willard Dere, M.D., senior vice president for Global Development and chief medical officer at Amgen. "We are excited at the potential for darbepoetin alfa to help heart failure patients, especially given the grievous nature of this illness. Despite the use of various currently available treatment options, the morbidity and mortality associated with heart failure remains high, and we hope that darbepoetin alfa will help address this important unmet medical need."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances